BRD4 and plasma cell myeloma: I-BET151 targets BRD4 in multiple myeloma cells and inhibits the expression of C-MYC and IRF4, thereby improving the transcription and translation levels of MICA, promoting the degranulation of NK cells and inducing anti-tumor immune response (29).